|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The application of human TCR in cancer immunotherapy has gained momentum with developments in tumor killing strategies using endogenous adaptive immune responses.
|
30919413 |
2019 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Gene expression profile of tumors in regression shows abundance of activated tumor infiltrating T cells with a more diversified TCR repertoire in animals treated with GAd and anti-PD1 compared to anti-PD1.
|
31217437 |
2019 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Pretreatment tumor TCR clonality and neoantigen load were marginally associated with best response with nivo/ipi (<i>P</i> = 0.04 and 0.05, respectively), but not with ipi/nivo.
|
30635271 |
2019 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Analysis of the TCR-Vβ-repertoire showed that a polyclonal T cell response was induced, suggesting the capacity of vaccine-activated CD4+ T cells to target multiple tumor (neo)antigens.
|
30956760 |
2019 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Combining gene transfer of the melanoma-specific TRP2-TCR with Tet-IL-12 engineering revealed that temporal induction of IL-12 was essential to inhibit the growth of B16F10 melanoma tumors.
|
30723575 |
2019 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Together, our results indicate that the naturally occurring 19305DP-TCR derived from CD4<sup>+</sup>CD8<sup>+</sup> double-positive αβ T cells, is a promising therapeutic TCR gene for effective and safe adoptive T-cell therapy in A*02<sup>+</sup> patients with NY-ESO-1-expressing tumor.
|
30626427 |
2019 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection.
|
30649750 |
2019 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
In addition, MHCII-expressing tumors contained more TCR clonotypes expanded to a larger degree than control tumors.
|
30334128 |
2019 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
In addition to using immune checkpoint blockade to reinvigorate existing but unresponsive tumor-specific T cells, alternative therapeutic approaches have been developed, including stimulation of polyclonal T cell cytolytic activity against tumors using bispecific T cell engager (BiTE) molecules that simultaneously engage the TCR complex and a tumor-associated Ag.
|
31253728 |
2019 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
While the exhaustion profiles of primary and recurrent GBM are comparable, TCR sequencing demonstrated a contracted repertoire in recurrent GBM, concomitant with an increased frequency of activated memory T cells in recurrent tumors.<i>Clin Cancer Res; 24(17); 4187-200.
|
29444930 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
In order to achieve broader application, an efficient method to identify TCR genes for an array of tumor antigens and HLA restriction elements is required.
|
29588318 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Here, we demonstrate that Fab fragments of UCHT1, which only bind monovalently to the γδ TCR, also enhanced tumor killing by expanded human Vγ9Vδ2 γδ T cells or pan-γδ T cells of the peripheral blood.
|
30038626 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
We showed cytotoxic potential of T cells engineered to express these TCRs <i>in vitro</i> and demonstrated regression of established tumors in a mouse model upon TCR gene therapy.<b>Conclusions:</b> Our findings demonstrate that MCC cells can be targeted by MCV Tag-specific TCRs.
|
29669806 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
We performed deep sequencing for TCR repertoire profiling on matched tumor/adjacent normal tissue from 15 NPC patients and peripheral blood from 39 NPC patients, 39 patients with other nasopharyngeal diseases, and 33 healthy controls.
|
30155576 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Moreover, TCR repertoire multifunction renewal could reverse tumor metastases from tumoricidal resistance into eventual regression as a blockade of cancer-sustaining Bmi-1/Nanog-Oct4-Sox2 renewal loop with sequent multivalent depletion of both migrating/in situ CSCs and non-stem terminal cancer cell subsets.
|
30150284 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Thus, optimal combination therapy increases TCR diversity with extended activation of selective CD8<sup>+</sup> T-cells specifically in the tumor but not in the periphery.
|
29348598 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Tumors that were MCPyV(+) had a strikingly more clonal (less diverse) intratumoral TCR repertoire than virus-negative tumors (p = 0.0001).
|
30482247 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Our results demonstrate that pharmacological inhibition of DGKα downstream of the TCR provides a gain-of-function effect that amplifies the DAG-dependent signaling cascade, an ability that could be exploited therapeutically to reinvigorate T cells to attack tumors.
|
29572701 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
We have identified AFP-specific murine TCR genes that can redirect human T cells to specifically recognize and kill HCC tumor cells, and those AFP<sub>158</sub> -specific TCRs have a great potential to engineer a patient's autologous T cells to treat HCC tumors.(Hepatology 2018).
|
29443377 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Recent studies have highlighted the promise of targeting tumor neoantigens to generate potent antitumor immune responses and provide strong motivation for improving our understanding of antigen-T-cell receptor (TCR) interactions.
|
30150207 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
In this paper, we review the emerging strategies of improving the homing of effector T cells (TILs, CARs, TCR engineered T cells, etc.) through genetic engineering with chemokine receptors matching the chemokines of the tumor microenvironment.
|
30126117 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Studying TCR T cell anti-tumor activity in a microfluidic intrahepatic tumor model.
|
30037462 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
More importantly, we demonstrated a critical role for type I IFN signaling in controlling the preferential accumulation in the tumor bed of a peculiar subset of γδT17 cells displaying a CD27<sup>-</sup> CD3<sup>bright</sup> phenotype (previously associated with the invariant Vγ6Vδ1<sup>+</sup> TCR).
|
29070614 |
2018 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Engraftment in mice and tumor infiltration of TCR transgenic T cells in the mice was evaluated.
|
28344885 |
2017 |
|
TRBV20OR9-2
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Despite this CAR-specific dysfunction, CAR-VZVSTs retained functional specificity for VZV antigens via their TCRs and GD2.CAR function was partially rescued by stimulation through the TCR or exposure to dendritic cell supernatants.<b>Conclusions:</b> Vaccination via the TCR may provide a means to reactivate CAR-T cells rendered dysfunctional by the tumor microenvironment (NCT01953900).<i></i>.
|
28183713 |
2017 |